6,7-Dihydroxybergamottin.

6,7-dihydroxybergamottin is a mechanism-based inhibitor of intestinal CYP3A4, the same enzyme quercetin inhibits at higher concentrations. Taken together they can raise the systemic exposure of anything that depends on gut-wall CYP3A4 for first-pass clearance. That is a plausible interaction to flag, not a benefit to seek. Anyone on prescription medicine should raise it with a pharmacist before combining citrus furanocoumarin material with concentrated flavonoid supplements.

Piperine is added to formulas specifically to slow gut-wall metabolism and raise the absorbed fraction of a co-ingredient. 6,7-dihydroxybergamottin does something similar through irreversible inactivation of CYP3A4. Stacking two absorption-modifying agents compounds an effect that is already hard to predict per person. The practical read is caution about medicine timing rather than an argument for combining them.

Curcumin is cleared fast at the gut wall and in the liver, which is why formulators bolt on absorption modifiers. Inhibiting intestinal CYP3A4 and efflux transport is one mechanistic route to a higher plasma curve. This is mechanism, not a demonstrated clinical pairing, and it also widens exposure to anything else in the stack. Read it as pharmacology rather than a dosing recommendation.

Hyperforin drives CYP3A4 expression upward through pregnane X receptor activation, so chronic use raises the clearance of many co-ingested compounds. Dihydroxybergamottin destroys existing enzyme molecules, lowering clearance until new protein is made. Combining them gives an unstable net effect that depends on timing and duration. This is one of the clearer reasons to keep citrus furanocoumarin exposure and enzyme-inducing botanicals apart.

CYP3A4 performs 23- and 24-hydroxylation steps that help clear vitamin D metabolites. Slowing that enzyme slows one arm of vitamin D disposal. The size of the shift in normal dietary exposure is small and has not been quantified in humans for this specific compound. It belongs on the page as mechanism, with no dosing implication attached.

Berberine absorption is limited mainly by efflux back into the gut lumen and by first-pass metabolism. Furanocoumarins that suppress both steps raise the absorbed fraction in principle. Nobody has measured that combination in people, so the claim stops at plausible mechanism. The same shift would apply to any other co-administered CYP3A4 substrate, which is the part worth noticing.

Silymarin shows CYP and glucuronidation inhibition in vitro, although human data at ordinary supplement doses look modest. Adding a mechanism-based CYP3A4 inactivator on top narrows the margin further. The interaction is theoretical at supplement-level intakes. It is listed so a formulator sees the overlap rather than assuming independence.